Abstract
Background/Objective:Mid-upper-arm circumference (MUAC) is a simple method of assessing nutritional status in children above 6 months of age. In 2007 World Health Organization (WHO) introduced a MUAC z-score for children above 3 months of age. We evaluated whether MUAC or MUAC z-score had the best ability to identify children with high short-term mortality risk in Guinea-Bissau.Subjects/ Methods:The Bandim Health Project visits children 3-monthly until 3 years of age. MUAC is measured and deaths are registered. We studied a high-mortality cohort of children born in 1995-96 and a lower mortality cohort of children born in 2005-06. The prognostic ability of MUAC and MUAC z-score to predict mortality within 1 and 3 months after the MUAC assessment were compared by area under the receiver operating characteristic curve, sensitivity and positive predictive value.Results:Compared with MUAC z-score, MUAC identified as malnourished more girls than boys (prevalence ratio (PR)1.74 (1.52;2.01)) and more children aged 6-11 months than children aged 12-35 months (1.59 (1.38;1.82)). There was no difference in the prognostic ability of MUAC and MUAC z-score to predict mortality for children aged 6-35 months. The prognostic ability was higher when mortality was lower. MUAC performed well in the youngest infants.Conclusion:In the age group 6-35 months, MUAC and MUAC z-score had the same prognostic ability to predict short-term mortality. As MUAC is easier to use in field settings, there is no need to use MUAC z-score to identify children with a high-mortality risk.
Originalsprog | Engelsk |
---|---|
Tidsskrift | European Journal of Clinical Nutrition |
Vol/bind | 66 |
Udgave nummer | 9 |
Sider (fra-til) | 998-1003 |
Antal sider | 6 |
ISSN | 0954-3007 |
DOI | |
Status | Udgivet - sep. 2012 |
Udgivet eksternt | Ja |
Bibliografisk note
Funding Information:The study received funding from The Danish Medical Research Council and Augustinus Fonden. JR received a Danida Travel Grant. PA holds a research professorship grant from the Novo Nordisk Foundation. CB is funded through an ERC Starting Grant (ERC-2009-StG-243149). The sponsors had no role in the study design, data collection, data analysis, data interpretation, or the writing of the report.